Jonathan S. Edwards Net Worth

The estimated Net Worth of Jonathan S. Edwards is at least $897 mil dollars as of 29 October 2019. Jonathan Edwards owns over 1,052,631 units of Phathom Pharmaceuticals Inc stock worth over $897,301 and over the last 5 years Jonathan sold PHAT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jonathan Edwards PHAT stock SEC Form 4 insiders trading

Jonathan has made over 1 trades of the Phathom Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jonathan bought 1,052,631 units of PHAT stock worth $19,999,989 on 29 October 2019.

The largest trade Jonathan's ever made was buying 1,052,631 units of Phathom Pharmaceuticals Inc stock on 29 October 2019 worth over $19,999,989. On average, Jonathan trades about 1,052,631 units every 0 days since 2019. As of 29 October 2019 Jonathan still owns at least 47,984 units of Phathom Pharmaceuticals Inc stock.

You can see the complete history of Jonathan Edwards stock trades at the bottom of the page.

What's Jonathan Edwards's mailing address?

Jonathan's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE, IL, 60089.

Insiders trading at Phathom Pharmaceuticals Inc

Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper, ePharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.

What does Phathom Pharmaceuticals Inc do?

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.

Complete history of Jonathan Edwards stock trades at Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc executives and stock owners

Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Terrie Curran,
  President, Chief Executive Officer, Director
• Terrie J. Curran,
  Pres, CEO & Director
• Dr. Azmi Nabulsi M.D., M.P.H.,
  Co-Founder & COO
• David Socks,
  Co-Founder, Chief Financial Officer, Treasurer, Director
• Azmi Nabulsi,
  Co-Founder, Chief Operating Officer
• David A. Socks,
  Co-Founder & Director
• Michael Cola,
  Independent Director
• Heidi Kunz,
  Independent Director
• Aditya Kohli,
  Chief Business Officer and Co-founder
• Tadataka Yamada,
  Independent Chairman of the Board
• James Topper,
  Independent Director
• Mark Stenhouse,
  Independent Director
• Asit Parikh,
  Independent Director
• Martin J. Gilligan,
  Chief Commercial Officer
• Dr. Eckhard Leifke M.D., Ph.D.,
  Chief Medical Officer
• Tom Harris,
  Head of Regulatory Affairs
• Lawrence Miller Esq., J.D.,
  Gen. Counsel & Sec.
• Joseph Hand J.D.,
  Chief Admin. Officer
• Anthony J. Guzzo,
  Principal Accounting Officer & Interim Principal Financial Officer
• Aditya Kohli Ph.D.,
  Co-Founder
• Frank Karbe,
  
• Todd P. Branning,
  Chief Financial Officer
• Heidi Fields,
  
• Capital Management, L.P.Ra ...,
  
• Life Sciences Ix, L.P.Fhmls...,
  
• Life Sciences Ix, L.P.Toppe...,
  
• Jonathan S. Edwards,
  Director
• Pharmaceutical Co Ltd Takeda,
  10% owner
• Anthony J. Guzzo,
  VP, Chief Accounting Officer
• Molly Henderson,
  CFO and CBO